We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesWave Life Sciences Ltd

Wave Life Sciences Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.4 USD -0.02 ( 0.58%)
Last update at 2026-11-12T15:42:00Z
VOLUME
431715
Market Cap
878.83M

Momentum Score

…

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.32
Low
3.53
High
52 Week Price Range
4.40
Low
21.73
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.42
Dividend Yield
-
Revenue TTM
65.37M
Revenue Per Share
0.35
Gross Profit TTM
-132.05M
Debt / Equity
0.03
ROE
-67.42%
Net Debt
-584.30M
ROCE
-37.61%
Diluted EPS TTM
-1.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -204.38M -97.01M -58.19M -161.14M -122.45M
Net income -204.38M -97.01M -57.51M -161.82M -122.25M
Selling general administrative 75.33M 59.02M 51.29M 50.51M 46.10M
Selling and marketing expenses - - 9.21M - -
Gross profit 33.88M 108.30M 113.31M 3.65M 40.96M
Reconciled depreciation 8.85M 8.66M 9.21M 10.11M 9.84M
Ebit -204.38M -97.01M -58.19M -172.83M -127.02M
Ebitda -195.53M -88.34M -48.98M -162.72M -127.05M
Depreciation and amortization 8.85M 8.66M 9.21M 10.11M -0.03M
Non operating income net other - - - 1.58M 4.57M
Operating income -215.38M -110.40M -68.00M -162.72M -127.02M
Other operating expenses 258.11M 218.71M 181.30M 166.37M 167.98M
Interest expense - - - -1.58M 14.43M
Tax provision 0.00M 0.00M -0.68M 0.68M -0.20M
Interest income - - - 1.57M -
Net interest income - - - 1.57M -
Income tax expense - - -0.68M 0.68M -0.20M
Total revenue 42.73M 108.30M 113.31M 3.65M 40.96M
Total operating expenses 249.26M 218.71M 181.30M 166.37M 167.98M
Cost of revenue 8.85M 8.66M 9.21M - -
Total other income expense net 11.01M 13.39M 9.81M 1.58M 4.57M
Net income from continuing ops -204.38M -97.01M -57.51M -161.82M -122.25M
Net income applicable to common shares - - - -161.82M -122.25M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 638.50M 352.21M 274.95M 146.39M 207.01M
Other current assets 11.47M 16.89M 13.94M 2.11M 5.42M
Total liab 112.27M 142.69M 227.44M 191.48M 174.51M
Total stockholder equity 526.23M 209.51M 47.50M -45.09M 32.50M
Other current liab 26.56M 21.08M 16.83M 17.55M 14.86M
Common stock 1616.48M 1175.18M 935.37M 802.83M 749.85M
Capital stock 1616.48M 1175.18M 935.37M 802.83M 749.85M
Retained earnings -1326.24M -1121.86M -1024.85M -967.34M -805.51M
Other liab - - - 79.96M 77.48M
Other assets - - - 3.72M 3.80M
Cash 602.07M 302.08M 200.35M 88.50M 150.56M
Total current liabilities 95.06M 110.95M 186.44M 71.52M 64.20M
Current deferred revenue 44.44M 65.97M 150.06M 31.56M 37.10M
Net debt -584.30M -276.67M -168.23M -50.88M -120.65M
Short term debt 8.36M 7.64M 6.71M 5.50M 4.96M
Short long term debt total 17.77M 25.40M 32.12M 37.61M 29.92M
Other stockholder equity 228.37M 156.45M 129.24M 119.44M 87.98M
Property plant equipment - - - 17.28M 22.27M
Total current assets 614.81M 320.39M 235.37M 98.54M 162.56M
Net tangible assets - - - -37.22M 40.37M
Net receivables 1.28M 1.42M 21.09M - 0.00M
Inventory - - 0.00M - -
Accounts payable 15.70M 16.26M 12.84M 16.91M 7.28M
Accumulated other comprehensive income -0.25M -0.26M -0.12M -0.03M 0.18M
Common stock total equity - - - 802.83M 749.85M
Retained earnings total equity - - - -967.34M -805.51M
Non currrent assets other 0.02M 3.81M 0.16M 3.72M 3.80M
Non current assets total 23.68M 31.81M 39.58M 47.85M 44.44M
Capital lease obligations 17.77M 25.40M 32.12M 37.61M 29.92M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.94M -1.11M -1.25M -0.56M
Change to liabilities - - - 12.23M -4.15M
Total cashflows from investing activities -0.72M -0.94M -1.11M -1.25M -0.56M
Total cash from financing activities 488.24M 253.89M 132.53M 67.19M 55.83M
Change to operating activities - - - - 2.04M
Net income -204.38M -97.01M -57.51M -161.82M -122.25M
Change in cash 300.04M 101.79M 111.89M -62.06M -33.93M
Begin period cash flow 302.08M 204.05M 92.16M 154.22M 188.15M
End period cash flow 602.07M 305.84M 204.05M 92.16M 154.22M
Total cash from operating activities -187.49M -151.03M -19.43M -127.78M -88.99M
Issuance of capital stock 472.49M 236.18M 131.28M 52.33M 54.97M
Depreciation 8.85M 8.66M 9.21M 10.11M 9.84M
Other cashflows from investing activities -0.72M -0.94M - 0.11M -
Change to inventory - - - - 2.04M
Change to account receivables 0.15M 19.66M -21.09M 0.00M 30.00M
Sale purchase of stock - - - 66.08M 55.83M
Other cashflows from financing activities 488.24M 17.71M 1.26M 14.86M 0.86M
Change to netincome - - - 17.21M 16.41M
Capital expenditures 0.72M 0.94M 1.11M 1.36M 0.56M
Change receivables - - - - 30.00M
Cash flows other operating - - - -1.97M -16.49M
Cash and cash equivalents changes - - - -61.85M -33.73M
Change in working capital -16.94M -75.82M 19.08M 6.72M 7.01M
Stock based compensation 24.97M 13.14M 9.79M 17.19M 16.41M
Other non cash items 24.97M -75.20M -24.85M 0.01M 25.13M
Free cash flow -187.49M -151.96M -20.55M -129.14M -89.55M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
WVE
Wave Life Sciences Ltd		 -0.02
0.58%		 3.40 - - 13.44 1.94 6.61 -10.12
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Wave Life Sciences Ltd

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

733 Concord Avenue, Cambridge, MA, United States, 02138

617 949 2900

https://wavelifesciences.com

317

Name Title Year Born
Dr. Paul B. Bolno M.B.A., M.D., MBA Pres, CEO & Director 1974
Dr. Chandra Vargeese Ph.D. Chief Technology Officer & Head of Platform Discovery Sciences 1961
Mr. Kyle B. Moran CFA CFO & Principal Accounting Officer 1971
Kate Rausch Head of Investor Relations NA
Ms. Linda Rockett J.D. Gen. Counsel NA
Dr. Christopher Francis Ph.D. Sr. VP of Corp. Devel. & Head of Emerging Areas 1978
Mr. Jonathan Rosin Chief HR Officer NA
Dr. Sridhar Vaddeboina Ph.D. Sr. VP of Chemistry, Manufacturing & Controls NA
Ms. Anne-Marie Li-Kwai-Cheung Chief Devel. Officer NA
Dr. Stephen L. Lake Sr. VP & Head of Clinical Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…